Related Experiment Video
Updated: Nov 7, 2025

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem
Naoki Yoshikawa1, Hidemi Takeshima1, Masaaki Sekine2
1Department of Pharmacy, University of Miyazaki Hospital, Miyazaki 889-1692, Japan.
Abstract:
A polymorphism in the gene encoding the metabolic enzyme cytochrome P450 family 3 subfamily A member 5 (CYP3A5) is a particularly influential factor in the use of tacrolimus in Japanese patients. Those who are homozygotic for the *3 mutation lack CYP3A5 activity, which results in substantial individual differences in tacrolimus metabolism. The aim of this study was to analyze the relationship between individual differences in tacrolimus blood concentration changes and CYP3A5 polymorphisms in allogeneic hematopoietic stem cell transplantation recipients during the period of increasing blood concentration of the drug following treatment onset. This was a prospective observational cohort study, involving 20 patients administered tacrolimus by continuous infusion. The subjects were divided into the *1/*3 and *3/*3 groups based on CYP3A5 polymorphism analysis. The tacrolimus blood concentration/dose (C/D) ratio increased from day 1 and was largely stable on day 5, and a significant difference was observed between the *1/*3 and *3/*3 groups in the time course of the C/D ratio during this period (p < 0.05). This study reveals the effects of CYP3A5 polymorphism on continuous changes in tacrolimus blood concentration.
Related Concept Videos
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Therapeutic Drug Monitoring: Affecting Factors
Dosage Regimen: Multiple Oral Dosage
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

